Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters.

Takayuki KatsubeYuji InoueTakahiro FukuharaTakeshi KanoToshihiro Wajima

Published in: European journal of clinical pharmacology (2020)

In consideration with in vitro data, the in vivo and in silico results suggested no clinically significant DDI potential of lusutrombopag with other medical products via metabolic enzymes and transporters.

Keyphrases

healthcare
molecular docking
electronic health record
big data
risk assessment
machine learning
deep learning